Skip to main content

Table 1 HLA class I genotyping results of the 74 cell lines used in the study

From: Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68

Origin

Cell line

A Locus

B Locus

Cw Locus

Origin

Cell line

A Locus

B Locus

Cw Locus

Lung

A549

25, 30

18, 44

12, 16

Liver

Huh 7.5.1

11

54

1

 

$ A549 p107

25, 30

18, 44

12, 16

Melanoma

*$ 1858-MEL

01, 24

52, 55

01, 12

 

EKVX

1

37

6

 

#$ 1936-MEL

3

15/95, 4901

02, 07

 

HOP 92

03, 24

27, 47

01, 06

 

397-MEL

01, 25

08, 15/95

04, 07

 

# HOP62

03, 11

40, 56

01, 03

 

*$888-MEL

01, 24

52, 55

01, 12

 

*$ NCI-H1299

24

14

8

 

*A375

01, 02/92

44, 57

06, 16

 

NCI-H226

01, 24

07, 39

07, 12

 

LOX-IMVI

11, 29

07, 44

07, 16

 

NCI-H23

8001

50

6

 

M14

11, 24

15/95, 35

03, 04

 

NCI-H322M

29

44

16

 

SK-MEL-2

03, 26

35, 38

04, 12

 

NCI-H460

24, 68

35, 51

03, 15

 

SK-MEL-28

11

40

3

 

NCI-H522

02/92

44, 55

03, 05

 

#SK-MEL-5

02/92, 32

39, 44

05, 12

Cervix

*Siha

24

40

3

 

#UACC-257

01, 32

08, 40

07, 15

CNS

SF-268

01, 32

08, 40

02, 07

 

# UACC-62

02/92, 11

07, 40

03, 07

 

SF-295

01, 26

07, 55

03, 07

Ovarian

IGR-OV1

24, 33

49

7

 

SF-539

02/92

08, 35

04, 07

 

NCI/ADR-RES

01, 25

57

6

 

SNB-19

02/92

18

5

 

OVCAR-3

02/92, 29

07, 58

7

 

SNB-75

02/92, 11

35, 39

04, 12

 

OVCAR-3 p7

02/92, 29

07, 58

7

 

U251

02/92

18

5

 

# OVCAR-4

02/92

18, 44

05, 07

Colon

COLO 205

01, 02/92

07, 08

7

 

OVCAR-5

01, 02/92

08, 44

05, 07

 

HCC 2998

02/92, 24

37, 40

04, 06

 

OVCAR-8

01, 25

57

6

 

HCT-116

01, 02/92

18, 45

05, 07

 

SK-OV-3

03, 68

18, 35

04, 05

 

HCT-15

02/92, 24

08, 35

04, 07

Pancreas

*$ MIA Paca2

24, 32

40, 40

2

 

HT-29

01, 24

35, 44

4

 

*$ Panc 1

02/92, 11

38

12

 

$ HT-29 p155

01, 24

35, 44

4

Renal

786-0

3

07, 44

05, 07

 

KM12

02/92

7

7

 

A498

02/92

8

7

 

SW-620

02/92, 24

07, 15/95

7

 

ACHN

26

49

7

Breast

BT-549

01, 02/92

1517, 55

03, 07

 

# CAKI-1

02/92, 24

37, 40

04, 06

 

*$GI-101A

29

07, 08

07, 15

 

RXF 393

02,24

1444

50,802

 

# HS-578T

03, 11

40, 56

01, 03

 

SN12C

03, 24

07, 44

05, 07

 

MCF-7

02/92

18, 44

5

 

TK-10

33

14

8

 

$ MDA-MB-231 p41

02/92

40, 41

02, 17

 

UO-31

01, 03

07, 14

07, 08

 

MDA-MB-231 p6

02/92

40, 41

02, 17

Hematopoietic

CCRF-CEM

01, 31

08, 40

03, 07

 

MDA-MB-435

11, 24

15/95, 35

03, 04

 

HL-60

1

57

6

 

T-47D

33

14

8

 

K-562

11, 31

18, 40

03, 05

Prostate

$ DU-145

03, 33

50, 57

6

 

MOLT-4

01, 25

18, 57

06, 12

 

PC-3 p35

01, 24

13, 55

01, 06

 

RPMI 8226

30,68

15,15

02.,03

 

PC-3 p7

01, 24

13, 55

01, 06

 

SR

02/92, 03

37, 39

06, 12

  1. ($) Cell lines previously characterized by our group for their in vivo responsiveness to GLV - 1h68 oncolityc therapies [12].
  2. Among all cells lines, 58 (78.3%) matched previous genotyping results conducted in our lab, 8 (10.8%) had not been previously genotyped (*) and 8 cell lines (10.8%) displayed a different genotype from our previous genotyping (#) [20].